Patents by Inventor Andrew G. Plaut
Andrew G. Plaut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160000857Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinenmia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: May 13, 2015Publication date: January 7, 2016Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 9044424Abstract: The present invention provides methods for modification and regulation of glucose metabolism by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to increase the plasma half-life of glucagon-like peptide 1 (GLP-1) but not sufficient to suppress the immune system of the animal.Type: GrantFiled: July 25, 2013Date of Patent: June 2, 2015Assignees: 1149336 Ontario, Inc., New England Medical Center Hospitals. Inc., Trustees of Tufts CollegeInventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 8841109Abstract: Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed.Type: GrantFiled: April 20, 2010Date of Patent: September 23, 2014Assignees: The University of Kansas, Tufts Medical Center, Inc.Inventors: Todd Holyoak, Jiazhou Qiu, Andrew G. Plaut
-
Publication number: 20140178472Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: July 25, 2013Publication date: June 26, 2014Applicants: Trustees of Tufts College, 1149336 Ontario, Inc., New England Medical Center Hospitals, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 8513190Abstract: The present invention provides methods for modification and regulation of type II diabetes by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to treat type II diabetes but not sufficient to suppress the immune system of the animal.Type: GrantFiled: November 16, 2011Date of Patent: August 20, 2013Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 8440191Abstract: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.Type: GrantFiled: November 17, 2006Date of Patent: May 14, 2013Assignee: Tufts Medical CenterInventors: Andrew G. Plaut, Jiazhou Qiu
-
Publication number: 20130095036Abstract: The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders.Type: ApplicationFiled: April 4, 2012Publication date: April 18, 2013Applicants: New England Medical Center Hospitals, Inc., RQ Bioscience, Inc.Inventors: Robert Qiu, Jiazhou Qiu, Andrew G. Plaut
-
Patent number: 8318669Abstract: The present invention provides methods for modification and regulation of glucagon-like peptide 1 (GLP-1) metabolism by administering therapeutically effective amounts of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to inhibit DPIV proteolysis of GLP-1 but not sufficient to suppress the immune system of the animal.Type: GrantFiled: November 9, 2010Date of Patent: November 27, 2012Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 8216568Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.Type: GrantFiled: July 21, 2008Date of Patent: July 10, 2012Assignee: Tufts Medical CenterInventors: Andrew G. Plaut, Jiazhou Qiu
-
Publication number: 20120165252Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: November 16, 2011Publication date: June 28, 2012Applicants: Trustees of Tufts College, 1149336 Ontario, Inc., New England Medical Center Hospitals, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Publication number: 20120114629Abstract: Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed.Type: ApplicationFiled: April 20, 2010Publication date: May 10, 2012Applicant: TUFTS MEDICAL CENTER, INC.Inventors: Todd Holyoak, Jiazhou Qiu, Andrew G. Plaut
-
Publication number: 20110172149Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: November 9, 2010Publication date: July 14, 2011Applicants: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 7829530Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal but not sufficient to suppress the animal's immune system.Type: GrantFiled: November 26, 2008Date of Patent: November 9, 2010Assignees: Trustees of Tufts College, New England Medical Center Hospitals, 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Publication number: 20100015044Abstract: The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders.Type: ApplicationFiled: August 3, 2006Publication date: January 21, 2010Inventors: Robert Qiu, Jiazhou Qiu, Andrew G. Plaut
-
Publication number: 20090317381Abstract: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.Type: ApplicationFiled: November 17, 2006Publication date: December 24, 2009Applicant: TUFTS MEDICAL CENTERInventors: Andrew G. Plaut, Jiazhou Qiu
-
Publication number: 20090130084Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.Type: ApplicationFiled: July 21, 2008Publication date: May 21, 2009Applicant: TUFTS MEDICAL CENTERInventors: Andrew G. Plaut, Jiazhou Qiu
-
Publication number: 20090082309Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: November 26, 2008Publication date: March 26, 2009Applicant: Trustees of Tufts CollegeInventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Publication number: 20090041746Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.Type: ApplicationFiled: July 21, 2008Publication date: February 12, 2009Applicant: TUFTS MEDICAL CENTERInventors: Andrew G. Plaut, Jiazhou Qiu
-
Patent number: 7459428Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.Type: GrantFiled: July 17, 2006Date of Patent: December 2, 2008Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 7407653Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.Type: GrantFiled: August 19, 2004Date of Patent: August 5, 2008Assignee: Tufts Medical Center, Inc.Inventors: Andrew G. Plaut, Jiazhou Qiu